2. Signaling Pathways
  3. Immunology/Inflammation
  4. PGE synthase

PGE synthase

Prostaglandin E synthase

PGE synthase

Related Products

PDF 0.49 MB

PGE synthase (Prostaglandin E synthase), which converts cyclooxygenase (COX)-derived prostaglandin H2 (PGH2) to PGE2, is known to comprise a group of at least three structurally and biologically distinct enzymes. There are membrane-associated PGES (mPGES)-1, mPGES-2, and cytosolic PGES (cPGES).

mPGES-1 is a perinuclear protein that is markedly induced by proinflammatory stimuli and downregulated by anti-inflammatory glucocorticoids as in the case of COX-2. It is functionally coupled with COX-2 in marked preference to COX-1. mPGES-2 is synthesized as a Golgi membrane-associated protein, and the proteolytic removal of the N-terminal hydrophobic domain leads to the formation of a mature cytosolic enzyme. This enzyme is rather constitutively expressed in various cells and tissues and is functionally coupled with both COX-1 and COX-2. cPGES is constitutively expressed in a wide variety of cells and is functionally linked to COX-1 to promote immediate PGE2 production.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-10439
    HPGDS inhibitor 1
    		Inhibitor 99.42%
    HPGDS inhibitor 1 is a potent, selective and orally active Hematopoietic Prostaglandin D Synthase (HPGDS) inhibitor with an IC50s of 0.6 nM and 32 nM in enzyme and cellular assays, respectively. HPGDS inhibitor 1 does not inhibit human L-PGDS, mPGES, COX-1, COX-2, or 5-LOX.
    HPGDS inhibitor 1
  • HY-139589
    Zaloglanstat
    		Inhibitor 98.50%
    Zaloglanstat (ISC-27864; GRC-27864) is a selective, orally active microsomal mPGES-1 inhibitor. Zaloglanstat has an IC50 of 5 nM for human mPGES-1 without significant inhibitory effect on COX-1/2 (IC50 >10 μM). Zaloglanstat blocks the conversion of arachidonic acid metabolite prostaglandin PGH2 to prostaglandin PGE2, thereby inhibiting inflammation-related PGE2 overproduction and reducing inflammatory responses and pain. Zaloglanstat inhibits IL-1β-induced PGE2 release in A549 cells and human synovial fibroblasts in vitro. Zaloglanstat inhibits PGE2 release in pig and dog whole blood with IC50s ??of 161 nM and 154 nM, respectively. Zaloglanstat can be used in the study of asthma, osteoarthritis, and neurodegenerative diseases.
    Zaloglanstat
  • HY-15123
    (S)-Flurbiprofen
    		Inhibitor 99.88%
    (S)-Flurbiprofen is an active enantiomer of Flurbiprofen, with IC50 values of 0.48 μM and 0.47 μM for COX-1 and COX-2, respectively.
    (S)-Flurbiprofen
  • HY-W749694
    Cannflavin B
    		Inhibitor 98.36%
    Cannflavin B is a flavonoid compound that can be isolated from Cannabis sativa L. Cannflavin B is inhibitors of PGE2 release (IC50: 0.7 μM), mPGES-1 (IC50: 3.7 μM), and 5-lipoxygenase. Cannflavin B has multiple activities such as anti-inflammatory, antioxidant, anti-glycation, anti-ferroptosis, anti-tumor, and anti-Leishmania (IC50: 14 μM). Cannflavin B can also inhibit the TrkB-BDNF signaling pathway.
    Cannflavin B
  • HY-116474
    Viridicatol
    		Inhibitor 99.93%
    Viridicatol is a quinolone alkaloid with anti-inflammatory, antibacterial, antifungal, osteogenic and chondrogenic activities. Viridicatol reduces the phosphorylation levels of ERK, JNK, p38 and STAT6; inhibits MMP-2, MMP-9, NF-κB signaling pathway and PTP1B; downregulates genes related to mast cell activation; and binds to SHN3 to activate the Wnt/SHN3 signaling pathway. Viridicatol inhibits the expression of pro-inflammatory mediators and cytokines, and promotes osteogenic/chondrogenic differentiation. Viridicatol can be used in studies related to fibrosarcoma, allergy, bacterial infection, fungal infection and osteoporosis.
    Viridicatol
  • HY-N6029
    Dehydroevodiamine hydrochloride
    		99.80%
    Dehydroevodiamine hydrochloride is isolated from the leaves of Evodia rutaecarpa.
    Dehydroevodiamine hydrochloride
  • HY-105005
    Crisdesalazine
    		Inhibitor 98.92%
    Crisdesalazine (AAD-2004) is a microsomal prostaglandin E2 synthase-1 (mPGES-1) inhibitor. Crisdesalazine acts as a potent free radical scavenger that directly neutralizes reactive oxygen species (ROS) including hydrogen peroxide, exerting neuroprotective effects against apoptosis and axonal damage. Crisdesalazine inhibits PGE2 production, mediates inflammatory responses, and promotes the conversion of macrophages from the pro-inflammatory M1 phenotype to the anti-inflammatory M2 phenotype. Crisdesalazine is applicable to neuroprotection research in multiple sclerosis and spinal cord injury.
    Crisdesalazine
  • HY-N12586
    Pheophytin a
    		Inhibitor
    Pheophytin a is a multi-target inhibitor, anticancer agent, antioxidant and antiviral agent. Pheophytin a directly binds to and inhibits HCV-NS3/4A protease (IC50=0.89 μM) to block viral replication. Pheophytin a also scavenges free radicals, reduces ferric ions, and exhibits cytotoxic activity against breast cancer cells. Pheophytin a effectively inhibits LPS-induced production of nitric oxide, prostaglandin E2, NOS2 and COX-2, as well as various pro-inflammatory cytokines, by downregulating the transcription levels of inflammatory mediators and blocking the ERK1/2 and STAT-1 pathways. In a low nerve growth factor environment, Pheophytin a also enhances ERK1/2 phosphorylation and synergistically promotes neurite outgrowth through MAPK pathway. Pheophytin a can be used to investigate the pathogenic mechanisms of diseases including chronic hepatitis C, sepsis, breast cancer and Alzheimer's disease.
    Pheophytin a
  • HY-118282
    mPGES1-IN-7
    		Inhibitor 99.78%
    mPGES-1-IN-2 (compound III) is a benzimidazole-based mPGES-1 inhibitor that also inhibits adipophysin PGD synthase (I-PGDS) (5 μM, IR=60 %). mPGES-1-IN-2 reduces PGE2 production and tends to reduce levels of other prostaglandins. mPGES-1-IN-2 effectively inhibits acute inflammation in an air sac model stimulated by Carrageenan (HY-125474) in mice.
    mPGES1-IN-7
  • HY-B0683
    Limaprost
    		Agonist 99.78%
    Limaprost (OP1206) is a PGE1 analogue and a potent and orally active vasodilator. Limaprost increases blood flow and inhibits platelet aggregation. Limaprost pain relief, has antianginal effects, and can be used for ischaemic symptoms research.
    Limaprost
  • HY-179041
    SZ0232
    		Inhibitor 99.25%
    SZ0232 is a selective mPGES-2 inhibitor. SZ0232 binds to the active site of mPGES-2 via hydrogen bonds and π-π stacking, reduces the production of prostaglandin E2 (PGE2) and blocks the PGE2-EP3 pathway. SZ0232 regulates Ferroptosis by activating the heme-dependent p53/SLC7A11/GPX4 axis, inhibits lipid peroxidation, and protects renal tubules. SZ0232 enhances glucose-stimulated insulin secretion, inhibits β-cell senescence, and improves glucose homeostasis. SZ0232 reduces renal lipid accumulation, alleviates fibrosis, and ameliorates renal dysfunction in diabetic mice. SZ0232 inhibits renal cyst growth in polycystic kidney disease models. SZ0232 exhibits an insulinotropic effect that strengthens with the increase of animal age. SZ0232 can be used in studies related to type 2 diabetes, acute kidney injury, diabetic kidney disease, and autosomal dominant polycystic kidney disease.
    SZ0232
  • HY-W011309
    1-O-Hexadecylglycerol
    		Inhibitor 99.96%
    1-O-Hexadecylglycerol can up-regulate PPAR-γ expression, inhibit pGE2, and exhibit anti-inflammatory properties. 1-O-Hexadecylglycerol is effective in oral administration.
    1-O-Hexadecylglycerol
  • HY-162387
    UK4b
    		Inhibitor
    UK4b is a highly selective microsomal prostaglandin E2 synthase-1 (mPGES-1) inhibitor. UK4b possesses anti-inflammatory and analgesic effects. UK4b can block the growth of abdominal aortic aneurysms in mice.
    UK4b
  • HY-149202
    UT-11
    		Inhibitor 98.25%
    UT-11 is a potent and blood-brain barrier-permeable microsomal prostaglandin E synthase-1 (mPGES-1) inhibitor with IC50s of 0.10 μM and 2.00 μM for inhibiting PGE2 production in human (SK-N-AS) and murine (BV2) cells, respectively.
    UT-11
  • HY-N2106
    Dehydroevodiamine
    		Inhibitor 99.93%
    Dehydroevodiamine is a major bioactive quinazoline alkaloid isolated from Evodiae Fructus, has an antiarrhythmic effect in guinea-pig ventricular myocytes. Dehydroevodiamine inhibits LPS-induced iNOS, COX-2, prostaglandin E2 (PGE2) and nuclear factor-kappa B (NF-κB) expression in murine macrophage cells.
    Dehydroevodiamine
  • HY-12791
    hPGDS-IN-1
    		Inhibitor 99.92%
    hPGDS-IN-1 (Compound 2) is an hPGDS inhibitor with an IC50 of 12 nM (as measured by fluorescence polarization assay or EIA). hPGDS-IN-1 can be used in the research of allergic rhinitis and spinal cord neurons.
    hPGDS-IN-1
  • HY-B0270
    Suprofen
    		Inhibitor 99.09%
    Suprofen (TN-762) is a non-steroidal anti-inflammatory drug (NSAID).
    Suprofen
  • HY-15123R
    (S)-Flurbiprofen (Standard)
    		Inhibitor
    (S)-Flurbiprofen (Standard) is the analytical standard of (S)-Flurbiprofen. This product is intended for research and analytical applications. (S)-Flurbiprofen is an active enantiomer of Flurbiprofen, with IC50 values of 0.48 μM and 0.47 μM for COX-1 and COX-2, respectively.
    (S)-Flurbiprofen (Standard)
  • HY-110167
    TFC 007
    		Inhibitor 98.01%
    TFC-007, a selective hematopoietic prostaglandin D synthase (H-PGDS) inhibitor, show high inhibitory activity against H-PGDS enzyme (IC50 value of 83 nM). TFC-007 can be used for composing H-PGDS degradation inducer PROTAC(H-PGDS)-1 (TFC-007 binds to H-PGDS, and Pomalidomide binds to cereblon).
    TFC 007
  • HY-N8435
    Desoxo-narchinol A
    		Inhibitor 98.0%
    Desoxo-narchinol A is an orally active and potent anti-inflammatory agent. Desoxo-narchinol A can be isolated from the roots and rhizomes of Nardostachys jatamansi. Desoxo-narchinol A can be used for septic shock and inflammatory diseases research.
    Desoxo-narchinol A
Cat. No. Product Name / Synonyms Application Reactivity